- Timo grimmer is in the team - All endpoints of the clinical trial were reached I firmly believe that the drug works and that the CEO has done a good job no matter how much he is criticized.

The drug shows it works as is!

we have a drug, even many drugs, good for so many indications, to become a giant pharma, we are about to get billions in revenues.

$AVXL The improvements in the drug arm cannot be lucky. .

Our drug has no side effects.

I'm looking forward to seeing the long term AD data on ANVS and have the feeling it's going to end up being the best in class AD treatment as well.

Do not listen to any FUD this drug is the real deal.

$AVXL amazing to see the actual benefits to people and their families of this “miracle drug” as they call it

$AVXL Dr. Perry said we have a legendary drug which actually reverses AD and is safe unlike Adulhelm.

As the company continues to bring new treatments to market, it is likely that Biocryst will continue to be a leader in the field of rare disease treatment, providing both patients and investors alike with a brighter future.

gets a drug approved and immediately rewards shareholders!!!

A great drug like Orladeyo and this is what we get in terms of stock performance. FAILURES

We have a revenue generating drug thats just achieved 105% YoY growth.

If you want a derisked, undervalued company with an approved potential blockbuster drug that can provide steady and incremental ROI year over year, plus the added bonus of pipeline drugs adding more value in future… this stock will be a keeper

BCX 9930 was a very promising and exciting drug and it probably is.

$BCRX 9 slides in the presentation about why its "hard" to design drugs lmfao. hilarious.

"We believe BCX10013 has the potential to be a best-in-class treatment option with an oral, once-daily profile,”

Brags how great drug discovery platform

$BCRX -- Takeda’s HAE Drug Takhzyro Enjoying Positive Uptake in Japan -- Good news for Orla I guess .

Still Bull, still confident its a great drug.

$AUPH Since VOC is the only drug with any evidence classified as “High”, this stock will definitely be acquired above $30+++!!!

Blockbuster drug with improving sales and long patent life

BP would save so many lives with this drug.

1 Its approved and works great 2 Cause I see value.. IE BO GRABS 🍿

The ability to spread the drug’s benefits and get patients aware of the treatment would put us in a spotlight that no other way could.

• 97% gross margin (sheesh) • Excited bout new partnership(details soon) • drug price increase • 85% conversion psf's (stellar) • Tam is there, huge growth opportunity if they can get more sle patients tested, 75% would capture many.

LUPKYNIS is undoubtedly the best-in-class drug to treat Lupus Nephritis.

Before people start complaining about voc pricing, it’s cheaper than my drug, and life saving, whereas mine is joint sparing… What’s the bear thesis here again? ?